Begüm EVRANOS-AKSÖZ, Fatma KAYNAK ONURDAĞ, Erkan AKSÖZ, Selda ÖZGEN ÖZGACAR

Investigation of Antimicrobial and Antitubercular Activities of Some Hydrazone DerivedCompounds

A series of hydrazone derivatives were synthesized to investigate antifungal, antimicrobial and antitubercular activities. These activities were investigated against Escherichia coli, Escherichia coli isolate, Pseudomonas aeruginosa, Pseudomonas aeruginosaisolate (resistant to gentamicin), Staphylococcus aureus, Staphylococcus aureus isolate (MRSA), Enterococcusfaecalis, Enterococcusfaecalis isolate (VRE), Candida albicans, Candida krusei andMycobacteriumtuberculosis. Among the synthesized compounds B23had the best activity against Candida albicanswith 16 μg/mL MIC value and B24had the best activity against Staphylococcus aureus isolate (MRSA) with 16 μg/mL MIC value. The most effective compound against Mycobacteriumtuberculosis is found to be E9 with 32 μg/mL MIC value, achalcone derivative. However, all compounds were determined as ineffective against Escherichia coli and Escherichia coli isolate.

PDF

___

[1]Tiberi, S., Plessis, N., Walzl, G., Vjecha, M. J., Rao, M., Ntoumi, F., Mfinanga, S., Kapata, N., Mvaba, P., McHugh, T. D., Ippolito, G., Migliori, G. B., Maeurer, M. J., Zumla, A. 2018.Tuberculosis: progress and advances in development of new drugs, treatment regimens and host-directed therapies.Lancet Infectious Disease.18(7), e183-e198.

[2]Furin, J., Cox, H., Pai, M. 2019. Tuberculosis. Lancet, 393, 1642-1656.

[3]Evranos-Aksöz, B. 2014. New Drug candidates in tuberculosis treatment. Turkish Bulletin of Hygiene and Experimental Biology,71(4), 207-220.

[4]WHO. 2017. Global tuberculosis report, 2017. Geneva World Health Organization, https://reliefweb.int/report/world/global-tuberculosis-report-2017(Accessed date: 03.01.2020)

[5]Monedero, I.,Caminero, J. A. 2010.Management of multidrug-resistant tuberculosis: an update. Therapeutic Advances in Respiratory Disease, 4, 117-127.

[6]Yao, L.,LiangLiang, C.,JinYue, L.,WanMei,S.,Lili, S.,YiFan, L.,HuaiChen, L.2019. Ambient air pollution exposures and risk of drug-resistant tuberculosis. Environment International,124, 161-169.

[7]Tong, S. Y.,Davis, J. S.,Eichenberger, E.,Holland, T. L.,Fowler, V.G. 2015. Staphylococcus aureusinfections: epidemiology, pathophysiology, clinical manifestations, and management. Clinical Microbiology Reviews,28(3), 603-661.

[8]Rasigade, J. P., Vandenesch, F. 2014.Staphylococcus aureus: a pathogen with still unresolved issues. Infection Genetic Evolution,21, 510-514.

[9]Sancak, B. 2011. Staphylococcus aureusand antibiotic resistance. Bulletin of Microbiology, 45(3), 565-576.

[10]Bradley, S. F. 2002. Staphylococcus aureusinfections and antibiotic resistance in older adults.Clinical Infectious Diseases,34, 211-216.

[11]Xu, M.,Wu, P., Shen, F., Ji, J., Rakesh, K. P. 2019. Chalcone derivatives and their antibacterial activities: current development.Bioorganic Chemistry, 91, 103-133.

[12]Çetinkaya Şardan, Y. MRSA as a causative agent of nosocomial infection: prevention and control.İchastaliklaridergisi.org/managete/fu_folder/2007-03/html/2007-14-3-161-167.htm (Accessed date: 15.12.2019).

[13]Thomer, L.,Schneewind, O.,Missiakas, D. 2016. Pathogenesis of Staphylococcus aureusbloodstream infections. Annual Review of Pathology,11, 343-364.

[14]Lowy F. D. 1998. Staphylococcus aureusinfections.The New England Journal of Medicine,20, 339(8), 520-532.

[15]Sardi, J. C. O., Scorzoni, L., Bernardi, T., Fusco-Almeida, A. M., Mendes Giannini, M. J. S. 2013. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. Journal of Medical Microbiology, 62, 10-24.

[16]Rollas, S., Küçükgüzel, Ş.G. 2007. Biological activities of hydrazone derivatives. Molecules, 12, 1910-1939.

[17]Popiolek, L. 2017.Hydrazide –hydrazones as potential antimicrobial agents: overview of the literature since 2010. Medicinal Chemistry Research, 26, 287-301.

[18]Nasrullaev, A., Bozorov, K., Bobakulov, K., Zhao, J., Nie, L. F., Turgunov, K. K., Elmuradov, B., Aisa, H. A. 2019. Synthesis,characterization, andantimicrobial activity ofnovel hydrazone‑bearing tricyclic quinazolines. Research on Chemical Intermediates, 45, 2287-2300.

[19]Evranos-Aksoz, B., Baysal, I., Yabanoglu-Ciftci, S., Djikic, T., Yelekci, K., Ucar, G., Ertan, R. 2015. Synthesis and screening of human monoamine oxidase-A inhibitor effect of new 2-pyrazoline and hydrazone derivatives. Archive Der Pharmazie, 348, 743-756.

[20]Clinical and Laboratory Standards Institute (CLSI) (formerly NCCLS). 2006a. Performance standards for antimicrobial susceptibility testing 6thinformational supplement. CLSI M100-S16, Clinical and Laboratory Standards Institute, 940 West Valley Road, Wayne, Pennsylvania, USA.

[21]Clinical and Laboratory Standards Institute (CLSI) (formerly NCCLS). 2006b. Reference method for broth dilution antifungal susceptibility testing of yeast approved standard, M27-A, Clinical and Laboratory Standards Institute, 940 West Valley Road, Wayne, Pennsylvania, USA.

[22]Evranos-Aksöz, B.,Onurdağ, F. K.,Özgacar, S. Ö.2015. Antibacterial, antifungal and antimycobacterial activities of some pyrazoline, hydrazone and chalcone derivatives.Zeitschrift für Naturforschung C,70(7-8), 183-189.

23]Franzblau, S. G.,Witzig, R. S., McLaughlin, J. C., Torres, P., Madico, G., Hernandez, A., Degnan, M.T.,Cook, M. B.,Quenzer, V.K.,Ferguson, R.M.,Gilman, R.H.1998. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate alamar blue assay. Journal of Clinical Microbiology, 36, 362–366.